Role of Notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells

Cancer Research

Volumn 65, Issue 20, 2005, Pages 9269-9279

  Dalrymple, Susan ^a   Antony, Lizamma ^a   Xu, Yi ^a   Uzgare, Aarti R ^a   Arnold, Julia T ^a   Savaugeot, Jurga ^b   Sokoll, Lori J ^a,b   De Marzo, Angelo M ^a,b   Isaacs, John T ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DODECYL SULFATE SODIUM; GAMMA SECRETASE INHIBITOR; JAGGED1; NEUTRALIZING ANTIBODY; NOTCH1 RECEPTOR; UVOMORULIN;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CELL AGGREGATION; CELL CONTACT; CELL DENSITY; CELL GROWTH; CELL INTERACTION; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIUM; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATECTOMY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

CADHERINS; CALCIUM; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CULTURE MEDIA, SERUM-FREE; DNA-BINDING PROTEINS; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; TELOMERASE;

EID: 27144476439     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3989     Document Type: Article

References (50)

1. Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003;88:2972-82.
2. Isaacs JT. Control of cell proliferation and cell death in the normal and neoplastic prostate: a stem cell model. In Rogers CH, Coffey DS, Cunha G, Grayhack JT, Hinman F, Jr., Horton R, editors. Benign prostatic hyperplasia. Report no. NIH 87-2881. Bethesda (MD): Department of Health and Human Services, NIH; 1987. p. 85-94.
3. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004;117:3539-45.
4. Bonkhoff H, Fixemer T, Remberger K. Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate 1998;34:251-8.
5. De Marzo AM, Meeker AK, Epstein JI, Coffey DS. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol 1998;153:911-9.
6. van Leenders G, Dijkman H, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest 2000;80:1251-8.
7. Tran CP, Lin C, Yamashiro J, Reiter RE. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 2002;1:113-21.
8. van Leenders GJ, Gage WR, Hick JL, et al. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol 2003;162:1529-37.
9. Garraway LA, Lin D, Signoretti S, et al. Intermediate basal cells of the prostate: in vitro and in vivo characterization. Prostate 2003;55:206-18.
10. Uzgare AR, Xu Y, Isaacs JT. In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. J Cell Biochem 2004;91:196-205.
11. Gao J, Arnold JT, Isaacs JT. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 2001;61:5038-44.
12. Kurita T, Wang YZ, Donjacour AA, et al. Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 2001;8:192-200.
13. Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769-75.
14. Liu AY, Peehl DM. Characterization of cultured human prostatic epithelial cells by cluster designation antigen expression. Cell Tissue Res 2001;305:389-97.
15. Friedrichs B, Riedmiller H, Goebel HW, Rausch U, Aumuller G. Immunological characterization and activity of transglutaminases in human normal and malignant prostate and in prostate cancer cell lines. Urol Res 1995;23:301-10.
16. Luo J, Zha S, Gage WR, et al. α-Methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002;62:2220-6.
17. Wang XD, Shou J, Wong P, French DM, Gao WQ. Notch1-expressing cells are indispensable for prostatic branching morphogenesis during development and re-growth following castration and androgen replacement. J Biol Chem 2004;279:24733-44.
18. van Bokhoven A, Varella-Garcia M, Korch C, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-25.
19. Uzgare AR, Isaacs JT. Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res 2004;64:6190-9.
20. Kaighn ME, Kirk D, Szalay M, Lechner JF. Growth control of prostatic carcinoma cells in serum-free media: interrelationship of hormone response, cell density, and nutrient media. Proc Natl Acad Sci U S A 1981;78:5673-6.
21. Peehl DM, Stamey TA. Serial propagation of adult human prostatic epithelial cells with cholera toxin. In Vitro 1984;20:981-6.
22. Peehl DM, Stamey TA. Growth responses of normal, benign hyperplastic, and malignant human prostatic epithelial cells in vitro to cholera toxin, pituitary extract, and hydrocortisone. Prostate 1986;8:51-61.
23. Peehl DM, Stamey TA. Serum-free growth of adult human prostatic epithelial cells. In Vitro Cell Dev Biol 1986;22:82-90.
24. Peehl DM, Wong ST, Bazinet M, Stamey TA. In vitro studies of human prostatic epithelial cells: attempts to identify distinguishing features of malignant cells. Growth Factors 1989;1:237-50.
25. Chopra DP, Grignon DJ, Joiakim A, et al. Differential growth factor responses of epithelial cell cultures derived from normal human prostate, benign prostatic hyperplasia, and primary prostate carcinoma. J Cell Physiol 1996;169:269-80.
26. Yasunaga Y, Nakamura K, Ewing CM, Isaacs WB, Hukku B, Rhim JS. A novel human cell culture model for the study of familial prostate cancer. Cancer Res 2001;61:5969-73.
27. Yasunaga Y, Nakamura K, Ko D, et al. A novel human cancer culture model for the study of prostate cancer. Oncogene 2001;20:8036-41.
28. Brothman AR, Peehl DM, Patel AM, et al. Cytogenetic evaluation of 20 cultured primary prostatic tumors. Cancer Genet Cytogenet 1991;55:79-84.
29. Konig JJ, Teubel W, van Dongen JW, Hagemeijer A, Romijn JC, Schroder FH. Tissue culture loss of aneuploid cells from carcinomas of the prostate. Genes Chromosomes Cancer 1993;8:22-7.
30. Bright RK, Vocke CD, Emmert-Buck MR, et al. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res 1997;57: 995-1002.
31. Gindler EM, King JD. Rapid colorimetric determination of calcium in biologic fluids with methylthymol blue. Am J Clin Pathol 1972;58:376-82.
32. Denmeade SR, Sokoll LJ, Dalrymple S, et al. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 2003;54: 249-57.
33. Chin RK, Hawkins AL, Isaacs WB, Griffin CA. E1A transformed normal human prostate epithelial cells contain a 16q deletion. Cancer Genet Cytogenet 1998;103:155-63.
34. Shearman MS, Beher D, Clarke EE, et al. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid β-protein precursor γ-secretase activity. Biochemistry 2000;39:8698-704.
35. Chrucher I, Williams S, Kerrad S, et al. Design and synthesis of highly potent benzodiazepine γ-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4-hydroxy-N-((3S) -1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)butyramide by use of an asymmetric Ireland-Claisen rearrangement. J Med Chem 2003;46:2275-8.
36. Oda D, Bigler L, Mao EJ, Disteche CM. Chromosomal abnormalities in HPV-16-immortalized oral epithelial cells. Carcinogenesis 1996;17:2003-8.
37. Shou J, Ross S, Koeppen H, de Sauvage FJ, Gao W-Q. Dynamics of Notch expression during murine prostate development and tumorigenesis. Cancer Res 2001;61: 7291-7.
38. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 2003;194:237-55.
39. Struhl G, Adachi A. Nuclear access and action of Notch in vivo. Cell 1998;15:649-60.
40. Mumm JS, Schroeter EH, Saxena MT, et al. A ligand-induced extracellular cleavage regulates γ-secretase-like proteolytic activation of Notch-1. Mol Cell 2000;5:197-205.
41. LaVoie MJ, Selkoe DJ. The notch ligands, jagged and 6, are sequentially processed by α-secretase and presenilin/γ-secretase and release signaling fragments. J Biol Chem 2003;278:34427-37.
42. Ross DA, Kadesch T. Consequences of Notch-mediated induction of Jagged-1. Exp Cell Res 2004;296:173-82.
43. Rand MD, Grimm LM, Artavanis-Tsakonas S, et al. Calcium depletion dissociates and activates heterodimeric notch receptors. Mol Cell Biol 2000;20:1825-35.
44. 2+ dependence and mutational analysis reveal molecular details of E-cadherin homoassocation. EMBO J 1999;18:1738-47.
45. KIP1. J Cell Biol 1998;142:557-71.
46. Berges RR, Vukanovic J, Epstein JI, et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995;1:473-80.
47. Bussemakers MJ, van Moorselaar RJ, Giroldi LA, et al. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 1992;52:2916-22.
48. Umbas R, Schalken JA, Aalders TW, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992;52:5104-9.
49. Morton RA, Ewing CM, Nagafuchi A, Tsukita S, Isaacs WB. Reduction of E-cadherin levels and deletion of the α-catenin gene in human prostate cancer cells. Cancer Res 1993;53:3585-90.
50. Rashid MG, Sanda MG, Vallorosi CJ, Rios-Doria J, Rubin MA, Day ML. Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate. Cancer Res 2001;61:489-92.